Open AccessLobaplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: a 5-year follow-up of a randomized, open-label, phase II trial
Author(s) -
Wenting Yan,
Xiujuan Wu,
Shushu Wang,
Cheng He,
Ling Zhong,
Peng Tang,
Lin Ren,
Ting Zhang,
Xiaowei Qi,
Yi Zhang
Publication year - 2022
Publication title -
therapeutic advances in medical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.272
H-Index - 49
eISSN - 1758-8359
pISSN - 1758-8340
DOI - 10.1177/17588359221107111
Subject(s) - medicine , epirubicin , triple negative breast cancer , docetaxel , breast cancer , interquartile range , clinical endpoint , randomized controlled trial , gastroenterology , triple negative , adjuvant , chemotherapy , clinical trial , oncology , cancer
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom